

C-CAMP partners with the US-based QB3

12 October 2015 | News | By BioSpectrum Bureau

C-CAMP partners with the US-based QB3

Bangalore based Centre for Cellular and Molecular Platforms (C-CAMP), India's premier technology and innovation hub and The California Institute for Quantitative Biosciences (QB3), a San Francisco Bay-area based non-profit research and technology commercialization institute, have signed a Letter of Intent to create the US-Indo Life Science Sister Innovation Hub in the presence of Prime Minister Mr Narendra Modi when he visited the Bay Area in September.

The Innovation hub is aimed at fostering links between both these exciting innovative hubs and enhancing science based entrepreneurship, research, academia and businesses. Through this innovation hub, both the organizations plan to promote collaborations in scientific research, encourage co-development of innovation led products and push these technologies towards commercialization. Innovation-based start-ups will be nurtured and accelerated through incubation and funding opportunities by leveraging the existing entrepreneurial ecosystem in both countries.

Commenting on the Partnership, Dr Taslimarif Saiyed, director and COO, C-CAMP said, 'In the last couple of years, C-CAMP has worked extensively to establish a strong life science innovation and entrepreneurship ecosystem in and around Bangalore which nurtures many start-ups all over India with support from DBT and BIRAC. This partnership with QB3 provides an opportunity for C-CAMP to make stronger ties with the San Francisco Bay area cluster - one of the leading innovation ecosystems in the world. We are hopeful of some ground breaking collaborations and outcomes from this partnership in the coming years.'

'C-CAMP and QB3 both appreciate the key role that life science start-ups can play in improving the quality of life for our countries and globally. But C-CAMP and QB3 operate in cultures with different challenges and health care systems. By partnering, we hope to learn from each other,' said Prof. Regis Kelly, director, QB3.